Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study
Anthony R. Mato(Memorial Sloan Kettering Cancer Center), Nirav N. Shah(Medical College of Wisconsin), Wojciech Jurczak(The Maria Sklodowska-Curie National Research Institute of Oncology), Chan Y. Cheah(Sir Charles Gairdner Hospital), John M. Pagel(Swedish Medical Center), Jennifer A. Woyach(The Ohio State University), Bita Fakhri(University of California, San Francisco), Toby A. Eyre(University of Oxford), Nicole Lamanna(Columbia University Irving Medical Center), Manish R. Patel(Sarah Cannon), Alvaro J. Alencar(University of Miami), Ewa Lech‐Marańda(Instytut Hematologii i Transfuzjologi), William G. Wierda(The University of Texas MD Anderson Cancer Center), Catherine C. Coombs(University of North Carolina at Chapel Hill), James N. Gerson(UPMC Hillman Cancer Center), Paolo Ghia(IRCCS Ospedale San Raffaele), Steven Le Gouill(Centre d'Investigation Clinique de Nantes), David Lewis(University Hospitals Plymouth NHS Trust), Suchitra Sundaram(Roswell Park Comprehensive Cancer Center), Jonathon B. Cohen(Emory University), Ian W. Flinn(Tennessee Oncology), Constantine S. Tam(The Royal Melbourne Hospital), Minal Barve(Mary Crowley Cancer Research Center), Bryone J. Kuss(Flinders Medical Centre), Justin Taylor(University of Miami), Omar Abdel‐Wahab(Memorial Sloan Kettering Cancer Center), Stephen J. Schuster(University of Pennsylvania), M. Lia Palomba(Memorial Sloan Kettering Cancer Center), Katharine L. Lewis(Linear Clinical Research), Lindsey E. Roeker(Memorial Sloan Kettering Cancer Center), Matthew S. Davids(Dana-Farber Cancer Institute), Xuan Tan(Sir Charles Gairdner Hospital), Timothy S. Fenske(Medical College of Wisconsin), Johan Wallin(Loxo Oncology at Lilly (United States)), Donald E. Tsai(Loxo Oncology at Lilly (United States)), Nora Ku(Loxo Oncology at Lilly (United States)), Edward Y. Zhu(Loxo Oncology at Lilly (United States)), Jessica Chen(Loxo Oncology at Lilly (United States)), Ming Yin(Loxo Oncology at Lilly (United States)), Binoj C. Nair(Loxo Oncology at Lilly (United States)), Kevin Ebata(Loxo Oncology at Lilly (United States)), Narasimha Marella(Loxo Oncology at Lilly (United States)), Jennifer R. Brown(Harvard University), Michael Wang(The University of Texas MD Anderson Cancer Center)
Cited by 451Open Access